TSC-101
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Key Facts
Indication
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Phase
Phase 1
Status
Active; Part of ALLOHA™ trial
Company
About TScan Therapeutics
TScan Therapeutics is a clinical-stage biotech company focused on developing transformative TCR-T therapies for oncology, with a secondary research arm in autoimmunity. Founded in 2018, its core asset is a proprietary, high-throughput platform that discovers novel tumor antigens and therapeutic TCRs. Key achievements include an active Phase 1 trial for its lead candidate TSC-101 in post-transplant AML/MDS and FDA clearance for two additional heme candidates. The strategy leverages this platform to build a broad pipeline while advancing next-generation in vivo engineering approaches.
View full company profile